Showing results (21-30 of 56) with videos related to
Sort By:
Pageof 6
The American Journal of Managed Care|October 25, 2002
COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costsRick A Weideman, Kevin C Kelly, Catherine L Kelley, et al.Clinical Therapeutics|April 7, 2005
Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteersByron Cryer, Roger G Berlin, Stephen A Cooper, et al.Lancet (London, England)|February 13, 2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonLoren Laine, Sean P Curtis, Byron Cryer, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|July 10, 2003
Evaluation and management of patients with recurrent peptic ulcer disease after acid-reducing operations: a systematic reviewRichard H Turnage, George Sarosi, Byron Cryer, et al.Digestive Diseases and Sciences|August 30, 2017
Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation DisordersByron Cryer, Douglas A Drossman, William D Chey, et al.Human Pathology|September 28, 2013
Helicobacter gastritis induces changes in the oxyntic mucosa indistinguishable from the effects of proton pump inhibitorsKirthi R Kumar, Ramiz Iqbal, Elizabeth Coss, et al.Academic Medicine : Journal of the Association of American Medical Colleges|September 5, 2020
Mentoring Black Men in MedicineKelvin B Oliver, Mridula V Nadamuni, Christina Ahn, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 14, 2009
Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harmAndrew Moore, Ingvar Bjarnason, Byron Cryer, et al.The American Journal of Gastroenterology|February 13, 2013
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trialByron Cryer, Chunming Li, Lee S Simon, et al.Digestive Diseases and Sciences|April 15, 2008
Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control studyAli A Siddiqui, Stuart J Spechler, Sergio Huerta, et al.Pageof 6